JCL roundtable

Future of the lipid laboratory: Using the laboratory to manage the patient (part 2)

William Virgil Brown, Yehuda Handelsman, Seth Martin, Pamela B. Morris

Research output: Contribution to journalReview article

Abstract

The measurement of cholesterol and triglycerides as indicators of metabolic disorders and most particularly of vascular disease risk has been of growing importance to physicians and epidemiologists over the past century. This was refocused on the lipoproteins, the specific packages in blood that carry these lipids, by John Gofman, MD, PhD, and Don Fredrickson, MD, more than 50 years ago. We continue to learn about the metabolism of these large molecular structures and their relationship to arteriosclerosis as new genetic and interventional studies are published. The clinical laboratory has evolved to provide more focused information with measures that can help us assess risk and target our therapy more effectively. In this roundtable discussion, I had the opportunity to talk with physicians who consider lipoprotein management to be central features of their practice every day. They personally care for patients with metabolic disorders in which the lipoproteins have caused disease or are predicted to do so. They are well-versed on the way that science is leading us in our field. I believe that you will learn from their view of current needs regarding lipoprotein measures and the changes that may derive from ongoing scientific studies in our field.

Original languageEnglish (US)
Pages (from-to)846-854
Number of pages9
JournalJournal of Clinical Lipidology
Volume11
Issue number4
DOIs
StatePublished - Jul 1 2017

Fingerprint

Lipoproteins
Lipids
Physicians
Arteriosclerosis
Midazolam
Molecular Structure
Vascular Diseases
Patient Care
Triglycerides
Cholesterol
Therapeutics

Keywords

  • Cholesterol
  • Lipoprotein
  • Metabolic disorders
  • Metabolism
  • Triglycerides

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics
  • Cardiology and Cardiovascular Medicine

Cite this

JCL roundtable : Future of the lipid laboratory: Using the laboratory to manage the patient (part 2). / Brown, William Virgil; Handelsman, Yehuda; Martin, Seth; Morris, Pamela B.

In: Journal of Clinical Lipidology, Vol. 11, No. 4, 01.07.2017, p. 846-854.

Research output: Contribution to journalReview article

Brown, William Virgil ; Handelsman, Yehuda ; Martin, Seth ; Morris, Pamela B. / JCL roundtable : Future of the lipid laboratory: Using the laboratory to manage the patient (part 2). In: Journal of Clinical Lipidology. 2017 ; Vol. 11, No. 4. pp. 846-854.
@article{f507b5833dc24a3fb6d8cd29320d5d13,
title = "JCL roundtable: Future of the lipid laboratory: Using the laboratory to manage the patient (part 2)",
abstract = "The measurement of cholesterol and triglycerides as indicators of metabolic disorders and most particularly of vascular disease risk has been of growing importance to physicians and epidemiologists over the past century. This was refocused on the lipoproteins, the specific packages in blood that carry these lipids, by John Gofman, MD, PhD, and Don Fredrickson, MD, more than 50 years ago. We continue to learn about the metabolism of these large molecular structures and their relationship to arteriosclerosis as new genetic and interventional studies are published. The clinical laboratory has evolved to provide more focused information with measures that can help us assess risk and target our therapy more effectively. In this roundtable discussion, I had the opportunity to talk with physicians who consider lipoprotein management to be central features of their practice every day. They personally care for patients with metabolic disorders in which the lipoproteins have caused disease or are predicted to do so. They are well-versed on the way that science is leading us in our field. I believe that you will learn from their view of current needs regarding lipoprotein measures and the changes that may derive from ongoing scientific studies in our field.",
keywords = "Cholesterol, Lipoprotein, Metabolic disorders, Metabolism, Triglycerides",
author = "Brown, {William Virgil} and Yehuda Handelsman and Seth Martin and Morris, {Pamela B.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.jacl.2017.05.002",
language = "English (US)",
volume = "11",
pages = "846--854",
journal = "Journal of Clinical Lipidology",
issn = "1933-2874",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - JCL roundtable

T2 - Future of the lipid laboratory: Using the laboratory to manage the patient (part 2)

AU - Brown, William Virgil

AU - Handelsman, Yehuda

AU - Martin, Seth

AU - Morris, Pamela B.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - The measurement of cholesterol and triglycerides as indicators of metabolic disorders and most particularly of vascular disease risk has been of growing importance to physicians and epidemiologists over the past century. This was refocused on the lipoproteins, the specific packages in blood that carry these lipids, by John Gofman, MD, PhD, and Don Fredrickson, MD, more than 50 years ago. We continue to learn about the metabolism of these large molecular structures and their relationship to arteriosclerosis as new genetic and interventional studies are published. The clinical laboratory has evolved to provide more focused information with measures that can help us assess risk and target our therapy more effectively. In this roundtable discussion, I had the opportunity to talk with physicians who consider lipoprotein management to be central features of their practice every day. They personally care for patients with metabolic disorders in which the lipoproteins have caused disease or are predicted to do so. They are well-versed on the way that science is leading us in our field. I believe that you will learn from their view of current needs regarding lipoprotein measures and the changes that may derive from ongoing scientific studies in our field.

AB - The measurement of cholesterol and triglycerides as indicators of metabolic disorders and most particularly of vascular disease risk has been of growing importance to physicians and epidemiologists over the past century. This was refocused on the lipoproteins, the specific packages in blood that carry these lipids, by John Gofman, MD, PhD, and Don Fredrickson, MD, more than 50 years ago. We continue to learn about the metabolism of these large molecular structures and their relationship to arteriosclerosis as new genetic and interventional studies are published. The clinical laboratory has evolved to provide more focused information with measures that can help us assess risk and target our therapy more effectively. In this roundtable discussion, I had the opportunity to talk with physicians who consider lipoprotein management to be central features of their practice every day. They personally care for patients with metabolic disorders in which the lipoproteins have caused disease or are predicted to do so. They are well-versed on the way that science is leading us in our field. I believe that you will learn from their view of current needs regarding lipoprotein measures and the changes that may derive from ongoing scientific studies in our field.

KW - Cholesterol

KW - Lipoprotein

KW - Metabolic disorders

KW - Metabolism

KW - Triglycerides

UR - http://www.scopus.com/inward/record.url?scp=85028179466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028179466&partnerID=8YFLogxK

U2 - 10.1016/j.jacl.2017.05.002

DO - 10.1016/j.jacl.2017.05.002

M3 - Review article

VL - 11

SP - 846

EP - 854

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

SN - 1933-2874

IS - 4

ER -